Prognosis, Risk Factors and Clinical Features of Intraocular Recurrence in Primary Vitreoretinal Lymphoma

– The study investigated the clinical features, risk factors, and prognosis of intraocular recurrence in primary vitreoretinal lymphoma (PVRL).
– The study included 51 patients with PVRL, of which 14 patients experienced intraocular recurrence.
– The recurrence rate of intraocular involvement in PVRL was found to be 27.5% over a mean follow-up period of 42.5 months.


There was no significant difference in the central nervous system lymphoma (CNSL) relapse rate and median time to CNSL between the intraocular non-recurrence and intraocular recurrence groups.
– There was also no significant difference in survival outcomes, such as mortality rate and median overall survival, between the two groups.
Younger onset age, isolated PVRL, and no history of intravitreal chemotherapy were identified as independent risk factors for intraocular recurrences.
– Approximately 23.6% of patients with intraocular recurrence were asymptomatic and were diagnosed during routine follow-up.
– The rate of interleukin-10 (IL-10)/IL-6>1 was significantly lower at recurrence compared to the initial diagnosis, but the rate of IL-10≥50 pg/mL was high and not significantly different.
– The study suggests that intraocular recurrence does not have a significant impact on CNS manifestations or survival outcomes in patients with PVRL.
Younger patients have a higher risk of intraocular recurrence, and combined systemic and intravitreal chemotherapy may reduce intraocular recurrence.
– Regular ophthalmic follow-up and IL-10 testing are recommended to detect intraocular recurrence.

Webpage address: Liu, Shixue, et al. “Prognosis, Risk Factors and Clinical Features of Intraocular Recurrence in Primary Vitreoretinal Lymphoma.” Ophthalmology Retina, vol. 0, no. 0, 31 Oct. 2023, doi:10.1016/j.oret.2023.10.021.

Share With Your Friends:

WhatsApp
Telegram
Twitter
LinkedIn

Retina Ward of Farabi Eye Hospital

  • 0
  • 147
  • 174,883
  • 74,094
  • 14
  • 399
  • 2024-02-25